Volume 30, Number 4—April 2024
Research
Clostridium butyricum Bacteremia Associated with Probiotic Use, Japan
Ryuichi Minoda Sada
, Hiroo Matsuo, Daisuke Motooka, Satoshi Kutsuna, Shigeto Hamaguchi, Go Yamamoto, and Akiko Ueda
, Hiroo Matsuo, Daisuke Motooka, Satoshi Kutsuna, Shigeto Hamaguchi, Go Yamamoto, and Akiko Ueda
Table 1
Detailed clinical information on 5 patients with bacteremia caused by Clostridium butyricum based on a single-institute, retrospective study, Osaka University Hospital, Japan*
| Category |
Patient no. |
||||
| 1 |
2 |
3 |
4 |
5 |
|
| Age, y/sex |
68/F |
81/F |
77/M |
53/M |
19/F |
| Onset during hospitalization |
Yes |
Yes |
Yes |
Yes |
Yes |
| Diseases requiring hospitalization |
Chemotherapy |
Immunosuppressive treatment |
Post–aortic valve replacement |
Simultaneous pancreas and kidney transplant |
Double lung transplant |
| Underlying disease |
Esophageal cancer; gastric cancer |
Dermatomyositis |
Aortic valve regurgitation;
end-stage kidney disease |
End-stage kidney disease;
type 1 diabetes |
Idiopathic pulmonary arterial hypertension |
| Immunosuppression |
Yes |
Yes |
No |
Yes |
Yes |
| Charlson Comorbidity Index score |
2 |
1 |
4 |
6 |
1 |
| Central venous catheter insertion |
Yes |
No |
Yes |
No |
Yes |
| Concurrent MIYA-BM use |
Yes |
No, but previously administered another probiotic with C. butyricum |
Yes |
Yes |
Yes |
| Appropriate reason for the prescription of probiotics |
Yes (concomitant antibiotic use) |
NA |
Yes (concomitant antibiotic use) |
No |
No |
| Duration of use of probiotics, d |
8 |
NA |
12 |
91 |
30 |
| Polymicrobial bacteremia, microorganisms other than C. butyricum |
Yes (MSSA) |
Yes (Enterococcus faecium/MRCNS) |
None |
None |
None |
| Symptoms of onset |
Fever and diarrhea |
Fever and diarrhea |
Fever and abdominal pain, septic shock |
Fever and abdominal pain |
Fever and diarrhea |
| Diagnosis |
Enterocolitis |
Enterocolitis |
NOMI |
Duodenal perforation |
Enterocolitis |
| Antibiotics |
CMZ |
CTR |
MEM |
MEM |
VCM |
| 90-d mortality | Alive | Alive | Died | Alive | Alive |
*CMZ, cefmetazole; CTR, ceftriaxone; MEM, meropenem; MRCNS, methicillin-resistant coagulase-negative staphylococci; MSSA, methicillin-resistant Staphylococcus aureus; NA, not applicable; NOMI, nonocclusive mesenteric ischemia; VCM, vancomycin.
Page created: February 06, 2024
Page updated: March 20, 2024
Page reviewed: March 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.